Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors

Do any sulfonylureas (glimepiride, glipizide, or glyburide) associated increase the risk of cardiovascular events compared with dipeptidyl peptidase 4 inhibitors (DPP4is)?In this comparative effectiveness research study of electronic health records and claims from 48 165 individuals starting a second T2D agent after metformin, individuals treated with glipizide had a higher risk of a composite end point of myocardial infarction, ischemic stroke, heart failure hospitalization, and cardiovascular death than those treated with a DPP4i.These findings suggest that sulfonylureas, glipizide in particular, may not be the optimal agents in treatment of individuals with T2D at moderate cardiovascular risk.

Corresponding Author: Alexander Turchin, MD, MS, Division of Endocrinology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115 (aturchin@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.